Xiaowen Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xiaowen Wang has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Hongming Zhu
Tongji University
6 shared publications - Qin Liu
School of Computer Science and Technology, Tongji University, Shanghai, China
6 shared publications - Bowen Du
Tongji University, Shanghai, China
1 shared publication Danyi Chen
School of Software Engineering, Tongji University , Shanghai 201804, China
1 shared publication- Dongsheng Mao
Department of Clinical Laboratory Medicine, Shanghai Tenth People’s Hospital, School of Medicine, Tongji University, Shanghai, China
1 shared publication - Hongfei Fan
School of Computer Science and Technology, Tongji University, 4800 Cao’an Road, Jiading District, Shanghai 201804, P. R. China
1 shared publication
Latest Publications
- Open Access
- 6 January 2026
- Published by Springer Nature in BMC Bioinformatics
- Vol. 27 (1)
Hgtsynergy: a transfer learning method for predicting anticancer synergistic drug combinations based on a drug-drug interaction heterogeneous graph
Background: Drug combination therapy often outperforms monotherapy in cancer treatment, but the vast number of available drugs makes manual screening for synergistic combinations costly. Computational methods, especially deep learning, can reduce the search space by predicting likely synergistic drug combinations. Recent studies have improved drug synergy prediction by modeling associations among different biological entities, but drug–drug interactions have not been fully leveraged in this scenario, which motivated the work presented in this paper. Methods: This paper proposes a deep learning method named HGTSynergy to predict synergistic drug combinations, which employs a heterogeneous graph attention network and a tailored task to capture complex latent patterns in the drug network as prior knowledge. The learned knowledge is then transferred through a transfer learning framework to the downstream task of predicting drug synergy scores, effectively enhancing predictive performance. Results: A five-fold nested cross-validation is employed to train HGTSynergy. In the synergy regression task, HGTSynergy outperforms seven deep learning methods, achieving a mean squared error of 222.83, root mean squared error of 14.91, and Pearson correlation coefficient of 0.75. For the synergy classification task, it also surpasses other methods with an area under the receiver operating characteristic curve of 0.90, area under the precision–recall curve of 0.63, accuracy of 0.94, precision of 0.72, and Cohen’s Kappa of 0.52. The ablation study verifies that the heterogeneous graph attention network and the transfer learning framework both have a positive effect on prediction performance. Moreover, a series of analyses demonstrates that the proposed method exhibits strong generalization performance and interpretability. The case study further validates its consistency with prior research. Conclusions: This study suggests that drug synergy prediction can be improved by comprehensively modeling diverse drug–drug interaction types and leveraging transfer learning to extract prior knowledge from them. The ability of HGTSynergy to discover new anticancer synergistic drug combinations outperforms other state-of-the-art methods. HGTSynergy promises to be a powerful tool to pre-screen anticancer synergistic drug combinations.
- 6 January 2026
- Published by Springer Nature in BMC Bioinformatics
- Vol. 27 (1)
Open AccessHgtsynergy: a transfer learning method for predicting anticancer synergistic drug combinations based on a drug-drug interaction heterogeneous graph
Background: Drug combination therapy often outperforms monotherapy in cancer treatment, but the vast number of available drugs makes manual screening for synergistic combinations costly. Computational methods, especially deep learning, can reduce the search space by predicting likely synergistic drug combinations. Recent studies have improved drug synergy prediction by modeling associations among different biological entities, but drug–drug interactions have not been fully leveraged in this scenario, which motivated the work presented in this paper. Methods: This paper proposes a deep learning method named HGTSynergy to predict synergistic drug combinations, which employs a heterogeneous graph attention network and a tailored task to capture complex latent patterns in the drug network as prior knowledge. The learned knowledge is then transferred through a transfer learning framework to the downstream task of predicting drug synergy scores, effectively enhancing predictive performance. Results: A five-fold nested cross-validation is employed to train HGTSynergy. In the synergy regression task, HGTSynergy outperforms seven deep learning methods, achieving a mean squared error of 222.83, root mean squared error of 14.91, and Pearson correlation coefficient of 0.75. For the synergy classification task, it also surpasses other methods with an area under the receiver operating characteristic curve of 0.90, area under the precision–recall curve of 0.63, accuracy of 0.94, precision of 0.72, and Cohen’s Kappa of 0.52. The ablation study verifies that the heterogeneous graph attention network and the transfer learning framework both have a positive effect on prediction performance. Moreover, a series of analyses demonstrates that the proposed method exhibits strong generalization performance and interpretability. The case study further validates its consistency with prior research. Conclusions: This study suggests that drug synergy prediction can be improved by comprehensively modeling diverse drug–drug interaction types and leveraging transfer learning to extract prior knowledge from them. The ability of HGTSynergy to discover new anticancer synergistic drug combinations outperforms other state-of-the-art methods. HGTSynergy promises to be a powerful tool to pre-screen anticancer synergistic drug combinations.
- 24 June 2025
- Published by Springer Nature
- p. 372-387
MTDS: Meta-Path Context Enhanced Drug Combination Synergy Prediction
- 24 June 2025
- Published by Springer Nature
- p. 372-387
MTDS: Meta-Path Context Enhanced Drug Combination Synergy Prediction
- 18 November 2024
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Journal of Biomedical and Health Informatics
- Vol. 29 (3) , 2297-2309
Fusing Micro- and Macro-Scale Information to Predict Anticancer Synergistic Drug Combinations
Drug combination therapy is highly regarded in cancer treatment. Computational methods offer a time- and cost-effective opportunity to explore the vast combination space. Although deep learning-based prediction methods lead the field, their generalization ability remains unsatisfactory. Few previous studies have the ability to finely characterize drugs and cell lines at both the micro-scale and macro-scale. Furthermore, the interaction of cross-scale information is often overlooked. These two points limit models' ability of predicting the synergism of drug combinations in cell lines. To address the issues, we propose a novel anticancer synergistic drug combination prediction method termed MMFSynergy in this article. The construction of MMFSynergy involves three phases. Firstly, MMFSynergy pretrains two micro encoders and a macro graph encoder, which can capture micro- or macro-scale information from large volumes of unlabeled data and generate generic features for drugs and proteins. Secondly, it represents drugs and proteins by fusing cross-scale information through a self-supervised task. Finally, it employs a Transformer Encoder-based model to predict synergy scores, taking representations of drugs in the combinations and the associated proteins of cell lines as input. We compared our method with eight advanced methods across three typical scenarios based on two public datasets. The results consistently demonstrated that the proposed method's generalization ability outperforms six advanced methods'. We also conducted experiments including but not limited to ablation study and case study to further exhibit the effectiveness of MMFSynergy.
- 18 November 2024
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Journal of Biomedical and Health Informatics
- Vol. 29 (3) , 2297-2309
Fusing Micro- and Macro-Scale Information to Predict Anticancer Synergistic Drug Combinations
Drug combination therapy is highly regarded in cancer treatment. Computational methods offer a time- and cost-effective opportunity to explore the vast combination space. Although deep learning-based prediction methods lead the field, their generalization ability remains unsatisfactory. Few previous studies have the ability to finely characterize drugs and cell lines at both the micro-scale and macro-scale. Furthermore, the interaction of cross-scale information is often overlooked. These two points limit models' ability of predicting the synergism of drug combinations in cell lines. To address the issues, we propose a novel anticancer synergistic drug combination prediction method termed MMFSynergy in this article. The construction of MMFSynergy involves three phases. Firstly, MMFSynergy pretrains two micro encoders and a macro graph encoder, which can capture micro- or macro-scale information from large volumes of unlabeled data and generate generic features for drugs and proteins. Secondly, it represents drugs and proteins by fusing cross-scale information through a self-supervised task. Finally, it employs a Transformer Encoder-based model to predict synergy scores, taking representations of drugs in the combinations and the associated proteins of cell lines as input. We compared our method with eight advanced methods across three typical scenarios based on two public datasets. The results consistently demonstrated that the proposed method's generalization ability outperforms six advanced methods'. We also conducted experiments including but not limited to ablation study and case study to further exhibit the effectiveness of MMFSynergy.
- 8 October 2023
- Published by Springer Nature
- p. 464-475
HetBiSyn: Predicting Anticancer Synergistic Drug Combinations Featuring Bi-perspective Drug Embedding with Heterogeneous Data
- 8 October 2023
- Published by Springer Nature
- p. 464-475
HetBiSyn: Predicting Anticancer Synergistic Drug Combinations Featuring Bi-perspective Drug Embedding with Heterogeneous Data
- Open Access
- 1 June 2023
- Published by Oxford University Press (OUP) in Bioinformatics
- Vol. 39 (6)
A complete graph-based approach with multi-task learning for predicting synergistic drug combinations
Motivation: Drug combination therapy shows significant advantages over monotherapy in cancer treatment. Since the combinational space is difficult to be traversed experimentally, identifying novel synergistic drug combinations based on computational methods has become a powerful tool for pre-screening. Among them, methods based on deep learning have far outperformed other methods. However, most deep learning-based methods are unstable and will give inconsistent predictions even by simply changing the input order of drugs. In addition, the insufficient experimental data of drug combination screening limits the generalization ability of existing models. These problems prevent the deep learning-based models from being in service. Results: In this article, we propose CGMS to address the above problems. CGMS models a drug combination and a cell line as a heterogeneous complete graph, and generates the whole-graph embedding to characterize their interaction by leveraging the heterogeneous graph attention network. Based on the whole-graph embedding, CGMS can make a stable, order-independent prediction. To enhance the generalization ability of CGMS, we apply the multi-task learning technique to train the model on drug synergy prediction task and drug sensitivity prediction task simultaneously. We compare CGMS’s generalization ability with six state-of-the-art methods on a public dataset, and CGMS significantly outperforms other methods in the leave-drug combination-out scenario, as well as in the leave-cell line-out and leave-drug-out scenarios. We further present the benefit of eliminating the order dependency and the discrimination power of whole-graph embeddings, interpret the rationality of the attention mechanism, and verify the contribution of multi-task learning. Availability and implementation: The code of CGMS is available via https://github.com/TOJSSE-iData/CGMS.
- 1 June 2023
- Published by Oxford University Press (OUP) in Bioinformatics
- Vol. 39 (6)
Open AccessA complete graph-based approach with multi-task learning for predicting synergistic drug combinations
Motivation: Drug combination therapy shows significant advantages over monotherapy in cancer treatment. Since the combinational space is difficult to be traversed experimentally, identifying novel synergistic drug combinations based on computational methods has become a powerful tool for pre-screening. Among them, methods based on deep learning have far outperformed other methods. However, most deep learning-based methods are unstable and will give inconsistent predictions even by simply changing the input order of drugs. In addition, the insufficient experimental data of drug combination screening limits the generalization ability of existing models. These problems prevent the deep learning-based models from being in service. Results: In this article, we propose CGMS to address the above problems. CGMS models a drug combination and a cell line as a heterogeneous complete graph, and generates the whole-graph embedding to characterize their interaction by leveraging the heterogeneous graph attention network. Based on the whole-graph embedding, CGMS can make a stable, order-independent prediction. To enhance the generalization ability of CGMS, we apply the multi-task learning technique to train the model on drug synergy prediction task and drug sensitivity prediction task simultaneously. We compare CGMS’s generalization ability with six state-of-the-art methods on a public dataset, and CGMS significantly outperforms other methods in the leave-drug combination-out scenario, as well as in the leave-cell line-out and leave-drug-out scenarios. We further present the benefit of eliminating the order dependency and the discrimination power of whole-graph embeddings, interpret the rationality of the attention mechanism, and verify the contribution of multi-task learning. Availability and implementation: The code of CGMS is available via https://github.com/TOJSSE-iData/CGMS.
- Open Access
FTRLIM: Distributed Instance Matching Framework for Large-Scale Knowledge Graph Fusion
Instance matching is a key task in knowledge graph fusion, and it is critical to improving the efficiency of instance matching, given the increasing scale of knowledge graphs. Blocking algorithms selecting candidate instance pairs for comparison is one of the effective methods to achieve the goal. In this paper, we propose a novel blocking algorithm named MultiObJ, which constructs indexes for instances based on the Ordered Joint of Multiple Objects’ features to limit the number of candidate instance pairs. Based on MultiObJ, we further propose a distributed framework named Follow-the-Regular-Leader Instance Matching (FTRLIM), which matches instances between large-scale knowledge graphs with approximately linear time complexity. FTRLIM has participated in OAEI 2019 and achieved the best matching quality with significantly efficiency. In this research, we construct three data collections based on a real-world large-scale knowledge graph. Experiment results on the constructed data collections and two real-world datasets indicate that MultiObJ and FTRLIM outperform other state-of-the-art methods.
Open AccessFTRLIM: Distributed Instance Matching Framework for Large-Scale Knowledge Graph Fusion
Instance matching is a key task in knowledge graph fusion, and it is critical to improving the efficiency of instance matching, given the increasing scale of knowledge graphs. Blocking algorithms selecting candidate instance pairs for comparison is one of the effective methods to achieve the goal. In this paper, we propose a novel blocking algorithm named MultiObJ, which constructs indexes for instances based on the Ordered Joint of Multiple Objects’ features to limit the number of candidate instance pairs. Based on MultiObJ, we further propose a distributed framework named Follow-the-Regular-Leader Instance Matching (FTRLIM), which matches instances between large-scale knowledge graphs with approximately linear time complexity. FTRLIM has participated in OAEI 2019 and achieved the best matching quality with significantly efficiency. In this research, we construct three data collections based on a real-world large-scale knowledge graph. Experiment results on the constructed data collections and two real-world datasets indicate that MultiObJ and FTRLIM outperform other state-of-the-art methods.